ArticleKidney diseases (Basel, Switzerland)
External Validation of the Post-Biopsy International IgA Nephropathy Prediction Tool Models over Extended Follow-Up in an Asian Cohort.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- External validation of the updated international IgA nephropathy prediction tool in a Chinese population.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The post-biopsy International IgA Nephropathy Prediction Tool (IIgAN-PT) models were updated to assess progression risk 1 or 2 years after biopsy. This study externally validated both models in a contemporary Asian cohort with extended follow-up to evaluate long-term predictive performance. Methods: We included 1,296 Chinese patients with biopsy-proven IgAN. The primary outcome was a composite of end-stage kidney disease or a 50% decline in estimated glomerular filtration rate (eGFR) within 1 year post-biopsy. Model performance was evaluated using the coefficient of determination ( Results: Over a median follow-up of 4.5 years (IQR: 2.2-7.6), 20.2% of patients experienced the primary outcome. Models with and without race demonstrated excellent performance, with Conclusion: The post-biopsy IIgAN-PT models demonstrated good predictive performance and may support individualized risk stratification and treatment decisions in IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.